Ipamorelin vs PT-141
Ipamorelin and PT-141 are both peptide compounds evaluated on Vial: Ipamorelin is available as a compounded preparation with clinical-trial evidence, and PT-141 is FDA approved with FDA-approval-level clinical evidence, offered by 20 and 9 verified providers respectively.
Vial summary · compiled from public records
At a glance
PT-141
Sold as Vyleesi
- Category
- Peptide
- FDA / legal status
- FDA Approved
- Route
- Subcutaneous
Side by side
| Field | Ipamorelin | PT-141 |
|---|---|---|
| Category | Peptide | Peptide |
| Brand names | — | Vyleesi |
| FDA / legal status | Compoundable | FDA Approved |
| Evidence tier | Clinical Trials | FDA Approved |
| Administration route | Subcutaneous | Subcutaneous |
| Compounding access | Available through 503A and 503B compounding pharmacies | FDA-approved product, dispensed by prescription |
| Providers on Vial | 20 listed | 9 listed |
| Typical price band | $$ to $$$ | $$ |
Verified providers offering each
Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
About each compound
About Ipamorelin
A synthetic pentapeptide growth hormone secretagogue, ipamorelin selectively stimulates pituitary release of growth hormone by mimicking ghrelin and binding to the growth hormone secretagogue receptor (GHS-R). Unlike earlier secretagogues, it demonstrates high selectivity for GH release with minimal effect on cortisol, prolactin, or appetite-regulating hormones. Research applications have focused on its potential use in growth hormone deficiency, age-related muscle loss, and bone metabolism studies.
About PT-141
A synthetic cyclic heptapeptide melanocortin receptor agonist, bremelanotide (PT-141) acts primarily on MC4 receptors in the central nervous system to modulate sexual arousal pathways. The compound increases sexual desire through direct neurological mechanisms rather than peripheral vascular effects. Its primary clinical application is the treatment of hypoactive sexual desire disorder in premenopausal women.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.